Daily Technical Summary Reports on Biotech Stocks -- Juno Therapeutics, Lexicon Pharma, NantKwest, and Nektar Therapeutics

NEW YORK, July 7, 2017 /PRNewswire/ --

If you want a Stock Review on JUNO, LXRX, NK or NKTR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. In today's pre-market research, DailyStockTracker.com monitors the current performances of Juno Therapeutics Inc. (NASDAQ: JUNO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), NantKwest Inc. (NASDAQ: NK), and Nektar Therapeutics (NASDAQ: NKTR). According to an article on Benzinga, the iShares NASDAQ Biotechnology Index has been up 11.70% thus far this month, compared to a 12.39% gain for the NYSE ARCA Biotech Index. Register now and get full and free access to these DailyStockTracker.com research reports at:

http://dailystocktracker.com/register/

Juno Therapeutics 

On Thursday, shares in Seattle, Washington headquartered Juno Therapeutics Inc. recorded a trading volume of 1.82 million shares. The stock ended at $29.61, declining 5.22% from the last trading session. The Company's shares have gained 22.36% in the last one month, 28.13% over the previous three months, and 57.08% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 17.79% and 23.59%, respectively. Furthermore, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have a Relative Strength Index (RSI) of 60.65.

On June 17^th, 2017, Juno Therapeutics presented data from the TRANSCEND trial of JCAR017 in relapsed and refractory aggressive B cell non-Hodgkin lymphoma at the 2017 International Conference on Malignant Lymphoma in Lugano, Switzerland. JCAR017 is the Company's investigative chimeric antigen receptor T cell product candidate that targets CD19, a protein expressed on the surface of almost all B cell malignancies, and uses a defined composition of CD4 to CD8 T cells and a 4-1BB costimulatory domain. Access our complete research report on JUNO for free at:

http://dailystocktracker.com/registration/?symbol=JUNO

Lexicon Pharma 

The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc.'s stock finished yesterday's session 2.66% lower at $16.12 with a total trading volume of 746,677 shares. The Company's shares have gained 7.90% in the last one month, 16.05% over the previous three months, and 16.56% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.98% and 3.18%, respectively. Furthermore, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 45.50.

On June 19^th, 2017, Lexicon Pharma announced that XERMELO™ (telotristat ethyl) 250 mg has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for neuroendocrine tumors patients with carcinoid syndrome diarrhea. The NCCN designated XERMELO together with somatostatin analog (SSA) therapy as a category 2A treatment for adults inadequately controlled by SSA therapy. XERMELO has also been included in the NCCN Drugs & Biologics Compendium. The complimentary research report on LXRX can be downloaded at:

http://dailystocktracker.com/registration/?symbol=LXRX

NantKwest 

At the close of trading on Thursday, shares in San Diego, California headquartered NantKwest Inc. saw a drop of 11.87%, ending the day at $6.98. The stock recorded a trading volume of 930,567 shares, which was above its three months average volume of 666,080 shares. The Company's shares have advanced 64.62% in the last one month, 120.89% in the previous three months, and 22.03% since the start of this year. The stock is trading 45.92% and 27.64% above its 50-day and 200-day moving averages, respectively. Moreover, shares of NantKwest, which develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the US, have an RSI of 58.18. Register for free on DailyStockTracker.com and get access to the latest report on NK at:

http://dailystocktracker.com/registration/?symbol=NK

Nektar Therapeutics 

San Francisco, California headquartered Nektar Therapeutics' shares ended the day 2.74% lower at $19.50 with a total trading volume of 754,524 shares. The stock has gained 58.92% on an YTD basis. The Company's shares are trading 1.56% above their 50-day moving average and 21.15% above their 200-day moving average. Additionally, shares of Nektar Therapeutics, which develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the US, have an RSI of 53.33. Download your free research report on NKTR at:

http://dailystocktracker.com/registration/?symbol=NKTR

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA